4506 — Sumitomo Pharma Share News
0.000.00%
Last trade - 00:00- ¥826bn
- ¥902bn
- ¥453bn
Brief: Sumitomo Pharma America Enters Into A Cooperative Research And Development Agreement With The National Cancer Institute To Advance Clinical Understanding Of Enzomenib
Will Extend Period Of Reduction In Executive Remuneration As Co Continues To Face Challenging Business Situation
Notice Regarding Company Split Of Asian Business, Execution Of Share Transfer Agreement And Shareholders’ Agreement with Marubeni Global Pharma Corp
Table: Sumitomo Pharma -2024/25 group forecast(IFRS)
Table: Sumitomo Pharma -9-MTH group results (IFRS)
Announces Results Of Early Retirement Program Offer
Japan's Nikkei posts weekly fall amid domestic election jitters
To Offer Early Retirement Program To About 700 Employees In Japan As Part Of Fundamental Business Structural Reforms
Table: Sumitomo Pharma -Q1 group results (IFRS)
Dsp-5336 Received U.S. FDA Fast-Track Designation For The Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
Brief: Sumitomo Pharma Announces that DSP-5336 Has Received FDA Fast Track Designation for the Treatment of Relapsed
Brief: After U.S. Job Cuts, Sumitomo Pharma Eyes Layoffs In Japan - Nikkei
Toru Kimura Appointed As President And CEO
Table: Sumitomo Pharma -2023/24 parent results
Table: Sumitomo Pharma -2023/24 group results (IFRS)
Brief: Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
Brief: Sumitomo Chemical: To Cut About 4,000 Jobs, Or 10% Of Consolidated Employees, By End Of March 2025
Table: Sumitomo Pharma -2023/24 group forecast(IFRS)
Roivant's anti-inflammatory drug succeeds in mid-stage study (updated)